Global HER2 Breast Cancer Test Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

Description

List of Tables

The global demand for HER2 Breast Cancer Test Market is presumed to reach the market size of nearly USD 844.27 MN by 2030 from USD 425.88 MN in 2022 with a CAGR of 7.9% under the study period 2023 - 2030.

The Her2 breast cancer test is a diagnostic test used to determine the HER2 (Human Epidermal Growth Factor Receptor 2) level of breast cancer cells. HER2 is a protein that plays a role in cell growth and division. In some breast cancer cases, there is an overexpression or amplification of the HER2 gene, leading to excess production of this protein. This overexpression is associated with more aggressive tumor behavior and a poorer prognosis. It is typically performed on a tissue sample obtained through a biopsy or surgery. The sample is analyzed using various laboratory techniques to assess the presence and quantity of HER2 protein or the amplification of the HER2 gene.

MARKET DYNAMICS:

The increasing awareness and screening efforts for breast cancer have highlighted the importance of HER2 testing in determining the appropriate treatment approach. Technological advancements in diagnostic techniques, such as immunohistochemistry and fluorescence in situ hybridization, have improved the accuracy of this test, further driving its demand. The development of targeted therapies specifically designed to inhibit the HER2 protein has revolutionized the treatment of HER2-positive breast cancer, increasing the need for HER2 testing to identify suitable candidates for these therapies. Additionally, the rising incidence of breast cancer globally has contributed to the growth of the market, as more patients require accurate tests. Regulatory guidelines and recommendations that emphasize its significance, along with the personalized medicine approach, have also fueled the market's expansion. Collectively, these factors have led to increased adoption of HER2 testing, improving treatment decision-making and patient outcomes in breast cancer management.

The research covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of her2 breast cancer test. The growth and trends of her2 breast cancer test industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the her2 breast cancer test market provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Test Type

Immunohistochemistry (IHC)
Fluorescence/Chromogenic In Situ Hybridization (FISH/CISH)

By End-User

Hospitals
Diagnostic Laboratories

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the HER2 Breast Cancer Test market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the her2 breast cancer test market include Abbott Molecular Inc., Biogenex Laboratories Inc., Leica Biosystems, Roche, Agilent Technologies, Mylab Discovery Solutions Pvt. Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized as per your need.

Product Code: VMR112111511

1 . PREFACE

1.1. Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . HER2 BREAST CANCER TEST - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Test Type
- 3.7.2 Market Attractiveness Analysis By End-User
- 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL HER2 BREAST CANCER TEST MARKET ANALYSIS BY TEST TYPE

5.1 Overview by Test Type
5.2 Historical and Forecast Data
5.3 Analysis by Test Type
5.4 Immunohistochemistry (IHC) Historic and Forecast Sales by Regions
5.5 Fluorescence/Chromogenic In Situ Hybridization (FISH/CISH) Historic and Forecast Sales by Regions

6 . GLOBAL HER2 BREAST CANCER TEST MARKET ANALYSIS BY END-USER

6.1 Overview by End-User
6.2 Historical and Forecast Data
6.3 Analysis by End-User
6.4 Hospitals Historic and Forecast Sales by Regions
6.5 Diagnostic Laboratories Historic and Forecast Sales by Regions

7 . GLOBAL HER2 BREAST CANCER TEST MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1. Overview, Historic and Forecast Data Sales Analysis
- 7.3.2. North America By Segment Sales Analysis
- 7.3.3. North America By Country Sales Analysis
- 7.3.4. United State Sales Analysis
- 7.3.5. Canada Sales Analysis
- 7.3.6. Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1. Overview, Historic and Forecast Data Sales Analysis
- 7.4.2. Europe by Segment Sales Analysis
- 7.4.3. Europe by Country Sales Analysis
- 7.4.4. United Kingdom Sales Analysis
- 7.4.5. France Sales Analysis
- 7.4.6. Germany Sales Analysis
- 7.4.7. Italy Sales Analysis
- 7.4.8. Russia Sales Analysis
- 7.4.9. Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1. Overview, Historic and Forecast Data Sales Analysis
- 7.5.2. Asia Pacific by Segment Sales Analysis
- 7.5.3. Asia Pacific by Country Sales Analysis
- 7.5.4. China Sales Analysis
- 7.5.5. India Sales Analysis
- 7.5.6. Japan Sales Analysis
- 7.5.7. South Korea Sales Analysis
- 7.5.8. Australia Sales Analysis
- 7.5.9. Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1. Overview, Historic and Forecast Data Sales Analysis
- 7.6.2. Latin America by Segment Sales Analysis
- 7.6.3. Latin America by Country Sales Analysis
- 7.6.4. Brazil Sales Analysis
- 7.6.5. Argentina Sales Analysis
- 7.6.6. Peru Sales Analysis
- 7.6.7. Chile Sales Analysis
- 7.6.8. Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1. Overview, Historic and Forecast Data Sales Analysis
- 7.7.2. Middle East & Africa by Segment Sales Analysis
- 7.7.3. Middle East & Africa by Country Sales Analysis
- 7.7.4. Saudi Arabia Sales Analysis
- 7.7.5. UAE Sales Analysis
- 7.7.6. Israel Sales Analysis
- 7.7.7. South Africa Sales Analysis
- 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE HER2 BREAST CANCER TEST COMPANIES

8.1. Her2 Breast Cancer Test Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9 . COMPANY PROFILES OF HER2 BREAST CANCER TEST INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Abbott Molecular Inc.
- 9.3.1. Company Overview
- 9.3.2. Company Revenue
- 9.3.3. Products
- 9.3.4. Recent Developments
9.4. Biogenex Laboratories Inc.
- 9.4.1. Company Overview
- 9.4.2. Company Revenue
- 9.4.3. Products
- 9.4.4. Recent Developments
9.5. Leica Biosystems
- 9.5.1. Company Overview
- 9.5.2. Company Revenue
- 9.5.3. Products
- 9.5.4. Recent Developments
9.6. Roche
- 9.6.1. Company Overview
- 9.6.2. Company Revenue
- 9.6.3. Products
- 9.6.4. Recent Developments
9.7. Agilent Technologies
- 9.7.1. Company Overview
- 9.7.2. Company Revenue
- 9.7.3. Products
- 9.7.4. Recent Developments
9.8. Mylab Discovery Solutions Pvt. Ltd.
- 9.8.1. Company Overview
- 9.8.2. Company Revenue
- 9.8.3. Products
- 9.8.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies